Catalog No.
DHJ26601
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG2-kappa
Clonality
Monoclonal
Target
IL-31RA, Interleukin-31 receptor subunit alpha, IL31RA, hGLM-R, ZcytoR17, IL-31R-alpha, GPL, CRL3, Cytokine receptor-like 3, IL-31R subunit alpha, IL-31 receptor subunit alpha, Gp130-like receptor, GLM-R, Gp130-like monocyte receptor
Concentration
2.5 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q8NI17
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CIM 331, CAS: 1476039-58-3,Nemolizumab
Clone ID
Nemolizumab
Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus, PMID: 32640132
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis, PMID: 32074418
Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus, PMID: 31449914
Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study, PMID: 29753033
New and Emerging Systemic Treatments for Atopic Dermatitis, PMID: 32519223
Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis, PMID: 28249150
What's New in Atopic Dermatitis, PMID: 30850043
Biological therapies for atopic dermatitis: An update, PMID: 30679974
Interleukin-31 and interleukin-31 receptor: New therapeutic targets for atopic dermatitis, PMID: 29524262
Efficacy of biologics in atopic dermatitis, PMID: 32003247
Drugs for atopic dermatitis, PMID: 32555122
Biologics for Atopic Dermatitis, PMID: 33012322
Nemolizumab in moderate to severe atopic dermatitis: An exploratory analysis of work productivity and activity impairment in a randomized phase II study, PMID: 31166620
New and Emerging Therapies for Pediatric Atopic Dermatitis, PMID: 31364023
Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis, PMID: 29098604
Probiotics for treating eczema, PMID: 30480774
Role of the Pruritic Cytokine IL-31 in Autoimmune Skin Diseases, PMID: 31281316
Emerging Treatment Options in Atopic Dermatitis: Systemic Therapies, PMID: 29320765
Dosage Optimization of Nemolizumab Using Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling and Simulation, PMID: 28703903
Current and emerging biologics for the treatment of pediatric atopic dermatitis, PMID: 33078990
Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study, PMID: 33711179
Efficacy and safety of nemolizumab for adult atopic dermatitis treatment: A meta-analysis of randomized clinical trials, PMID: 33470215
Novel Therapeutic Approaches and Targets for the Treatment of Atopic Dermatitis, PMID: 32525769
Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical study, PMID: 33754202
[No title available], PMID: 30787245
Breaking the Itch-Scratch Cycle in Prurigo Nodularis, PMID: 32074425
Efficacy and Safety of Nemolizumab for Treatment of Adult Atopic Dermatitis, PMID: 34213421
Emerging systemic therapies for atopic dermatitis: biologics, PMID: 33045848
Efficacy and Safety of Nemolizumab for Treatment of Adult Atopic Dermatitis: A Meta-analysis of Randomized Clinical Trials, PMID: 33876738
Itch in Atopic Dermatitis Management, PMID: 27578076
Itch Management: Treatments under Development, PMID: 27578074
Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis, PMID: 32507066
Novel drugs for the treatment of chronic pruritus, PMID: 30426802
Time to meaningful clinical response in reduction of itch in atopic dermatitis, PMID: 33292019
[New aspects in systemic treatment of atopic dermatitis], PMID: 29470609
[Current and upcoming treatments of adult atopic dermatitis], PMID: 29433635
Interleukin-31 and Pruritic Skin, PMID: 33924978
Recent advances in atopic dermatitis, PMID: 29273133
Interleukin-31 pathway and its role in atopic dermatitis: a systematic review, PMID: 28145790
Therapy for pruritus in the elderly: a review of treatment developments, PMID: 29493371
Biological Therapies for Atopic Dermatitis: A Systematic Review, PMID: 33735876
Novel systemic drugs in treatment of atopic dermatitis: results from phase II and phase III studies published in 2017/2018, PMID: 30095475
Chronic Pruritus: A Review of Neurophysiology and Associated Immune Neuromodulatory Treatments, PMID: 30248162
[What's new in dermatological treatment?], PMID: 29249252
Prurigo Nodularis: Review and Emerging Treatments, PMID: 34077168
The use of biologics in food allergy, PMID: 33966304
Interleukin-31 as a Clinical Target for Pruritus Treatment, PMID: 33644103
New and developing therapies for atopic dermatitis, PMID: 29641707
Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect, PMID: 33685604
What progress have we made in the treatment of atopic eczema? Putting the new biological therapies into a wider context, PMID: 28731235
For research use only. Not for human or drug use.
